Skip to main content
polskiPL
European Commission logo print header

Understanding cancer development in BRCA 1/2 mutation carriers for improved Early detection and Risk Control

Cel

Recent evidence demonstrates that cancer is overtaking cardiovascular disease as the number one cause of mortality in Europe. This is largely due to the lack of preventative measures for common (e.g. breast) or highly fatal (e.g. ovarian) human cancers. Most cancers are multifactorial in origin. The core hypothesis of this research programme is that the extremely high risk of BRCA1/2 germline mutation carriers to develop breast and ovarian cancer is a net consequence of cell-autonomous (direct effect of BRCA mutation in cells at risk) and cell non-autonomous (produced in distant organs and affecting organs at risk) factors which both trigger epigenetic, cancer-initiating effects.
The project’s aims are centered around the principles of systems medicine and built on a large cohort of BRCA mutation carriers and controls who will be offered newly established cancer screening programmes. We will uncover how ‘cell non-autonomous’ factors work, provide detail on the epigenetic changes in at-risk tissues and investigate whether these changes are mechanistically linked to cancer, study whether we can neutralise this process and measure success in the organs at risk, and ideally in easy to access samples such as blood, buccal and cervical cells.
In my Department for Women’s Cancer we have assembled a powerful interdisciplinary team including computational biologists, functionalists, immunologists and clinician scientists linked to leading patient advocacy groups which is extremely well placed to lead this pioneering project to develop the fundamental understanding of cancer development in women with BRCA mutations. To reset the epigenome, re-establishing normal cell identity and consequently reducing cancer risk without the need for surgery and being able to monitor the efficacy using multicellular epigenetic outcome predictors will be a major scientific and medical breakthrough and possibly applicable to other chronic diseases.

Dziedzina nauki

Słowa kluczowe

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

ERC-2016-ADG

Zobacz inne projekty w ramach tego zaproszenia

System finansowania

ERC-ADG - Advanced Grant

Instytucja przyjmująca

UNIVERSITAET INNSBRUCK
Wkład UE netto
€ 1 115 793,00
Adres
INNRAIN 52
6020 Innsbruck
Austria

Zobacz na mapie
Region
Westösterreich Tirol Innsbruck
Rodzaj działalności
Higher or Secondary Education Establishments
Linki
Koszt całkowity
€ 1 115 793,00

Beneficjenci (5)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 1 Lutego 2024

Moja broszura

Permalink: https://cordis.europa.eu/project/id/742432/pl

European Union, 2024